RNA sequencing of advanced glycation end product-stimulated human umbilical vein endothelial cells treated with sorafenib-rosiglitazone nanoparticles
This project investigates transcriptomic changes associated with self-assembled sorafenib-rosiglitazone nanoparticles (SRNPs) in an in vitro model of diabetes-associated endothelial injury. Human umbilical vein endothelial cells (HUVECs) were cultured under two conditions for 48 h: advanced glycation end products (AGEs) alone and AGEs plus SRNPs. Total RNA was extracted using a one-step column-based method and analyzed by high-throughput RNA sequencing. The dataset comprises six biological samples, with three biological replicates per group. The study was designed to characterize SRNP-associated changes in gene expression and biological processes related to angiogenesis, inflammation, hypoxic responses, and extracellular matrix organization in the context of diabetic retinopathy.